share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K：諾和諾德-股票回購計劃
美股SEC公告 ·  08/06 20:23
牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has successfully concluded its share repurchase program initiated on May 6, 2024. The program, which was part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024, aimed to repurchase B shares for up to DKK 2.2 billion between May 7 and August 5, 2024. As of the end date, the company has repurchased a total of 2,332,876 B shares at an average price of DKK 878.97, amounting to a transaction value of DKK 9,727,706,050. Following the completion of this phase, Novo Nordisk now holds 12,432,916 B shares as treasury shares, representing 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. The company, founded in 1923 and headquartered in Denmark, is committed to defeating serious chronic diseases and employs approximately 66,000 people worldwide.
Novo Nordisk A/S, a leading global healthcare company, has successfully concluded its share repurchase program initiated on May 6, 2024. The program, which was part of a larger DKK 20 billion buyback plan set to occur over a 12-month period starting February 6, 2024, aimed to repurchase B shares for up to DKK 2.2 billion between May 7 and August 5, 2024. As of the end date, the company has repurchased a total of 2,332,876 B shares at an average price of DKK 878.97, amounting to a transaction value of DKK 9,727,706,050. Following the completion of this phase, Novo Nordisk now holds 12,432,916 B shares as treasury shares, representing 0.3% of the share capital. The company's total share count, including treasury shares, stands at 4,465,000,000 A and B shares. Novo Nordisk's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. The company, founded in 1923 and headquartered in Denmark, is committed to defeating serious chronic diseases and employs approximately 66,000 people worldwide.
領先的全球醫療保健公司, 諾和諾德A/S已成功完成於2024年5月6日啓動的股票回購計劃.該計劃是大DKK 200億收購計劃的一部分,該計劃設置在2024年2月6日開始的爲期12個月的期限內進行，旨在在2024年5月7日至8月5日期間回購多達DKK 22億的B股.截至結束日期，該公司以平均價格DKK 878.97回購了總計23328760億股，交易價值爲DKK 9,727,706,050.完成此階段後，諾和諾德現持有124329160億股作爲庫藏股，佔股本的0.3%.該公司的總股本數，包括庫藏股, 爲44.65億A和B股。諾和諾德的股票在納斯達克哥本哈根上交易，其ADR在紐約證券交易所上市。該公司成立於1923年，總部設在丹麥，致力於戰勝嚴重的慢性疾病，全球擁有約66,000名員工。
領先的全球醫療保健公司, 諾和諾德A/S已成功完成於2024年5月6日啓動的股票回購計劃.該計劃是大DKK 200億收購計劃的一部分,該計劃設置在2024年2月6日開始的爲期12個月的期限內進行，旨在在2024年5月7日至8月5日期間回購多達DKK 22億的B股.截至結束日期，該公司以平均價格DKK 878.97回購了總計23328760億股，交易價值爲DKK 9,727,706,050.完成此階段後，諾和諾德現持有124329160億股作爲庫藏股，佔股本的0.3%.該公司的總股本數，包括庫藏股, 爲44.65億A和B股。諾和諾德的股票在納斯達克哥本哈根上交易，其ADR在紐約證券交易所上市。該公司成立於1923年，總部設在丹麥，致力於戰勝嚴重的慢性疾病，全球擁有約66,000名員工。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。